| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2012-08-14 | Ark Therapeutics (UK) EMD Millipore Corporation (USA - Germany) | viral based bioengineered vaccines and other live viral products | collaboration |
Production agreement | ||
| 2012-08-14 | Regulus Therapeutics (USA) AstraZeneca (UK) | microRNA therapeutics for three exclusive targets which are currently in pre-clinical development | atherosclerosis, cardiovascular diseass, metabolic diseases, cancers | R&D |
Cancer - Oncology - Cardiovascular diseases - Metabolic diseases | Development agreement |
| 2012-08-14 | Plasticell (UK) EMD Millipore (USA), the Life Science Division of Merck KGaA (Germany) | xeno-free mesenchymal stem cell differentiation media | licensing |
Technology - Services | Distribution agreement | |
| 2012-08-09 | AstraZeneca (UK) BMS (USA) | Onglyza® (saxagliptin - DPP-4 inhibitor), Kombiglyze® (saxagliptin and metformin HCI extended-release), Forxiga (dapagliflozin - SGLT2 inhibitor), other Almylin's assets | diabetes | collaboration |
Metabolic diseases | Collaboration agreement |
| 2012-08-09 | Curetis (Germany) Cempra Pharmaceuticals (USA) | Unyvero™ pneumonia molecular diagnostic system | community-acquired bacterial pneumonia | R&D |
Infectious diseases | R&D agreement |
| 2012-08-06 | Novartis (Switzerland) University of Pennsylvania (USA) | novel T-cell immunotherapies based on chimeric antigen receptor (CAR) technology | cancer | R&D - development - commercialisation | Cancer - Oncology | R&D agreement |
| 2012-08-06 | IBA Molecular (Belgium) Piramal (India) | 18F-Florbetaben | Alzheimer\'s disease | manufacturing |
Neurodegenerative diseases | Production agreement |
| 2012-08-05 | Chiesi Farmaceutici (Italy) Kamada (Israel) | inhaled alpha-1 antitrypsin | Alpha-1 Antitrypsin Deficiency (AATD, or Inherited Emphysema) | Genetic diseases - Rare diseases | Distribution agreement | |
| 2012-08-03 | Xoma (USA - CA) Laboratoires Servier (France) Boehringer Ingelheim (Germany) | gevokizumab | Behçet's uveitis | manufacturing |
Ophtalmological diseases - Rare diseases | Production agreement |
| 2012-08-03 | Novartis (Switzerland) Marina Biotech (USA) | Conformationally Restricted Nucleotide (CRN) technology for the development of both single- and double-stranded oligonucleotide therapeutic | licensing |
Licensing agreement | ||
| 2012-08-03 | Capstone Therapeutics (USA) LipimetiX (UK) | Apo E mimetic peptides including Apo E Mimetic Molecule — AEM-28 | Homozygous Familial Hypercholesterolemia | joint-venture (JV) | Rare diseases - Genetic diseases - Cardiovascular diseases | |
| 2012-08-02 | Lonza (Switzerland) iPS Academia Japan (Japan) | induced pluripotent stem cell (iPSC) patent portfolio | licensing | |||
| 2012-08-02 | Alliance Pharma (UK) AstraZeneca (UK) | antimalarial brands Paludrine™, Avloclor™ and Savarine™ | acquisition |
Parasitic diseases | Product acquisition | |
| 2012-08-02 | CEVEC Pharmaceuticals (Germany) Paragon Bioservices (USA) | know-how and patents (on CAP and CAP-T cell expression system) to develop stable cell lines | licensing |
Licensing agreement | ||
| 2012-07-31 | Vivalis (France) undisclosed party utilizing Vivalis’ proprietary EB66® cell line | EB66® cell line | undisclosed | developement |
undisclosed | Development agreement |
| 2012-07-30 | Sensorion Pharmaceuticals (France) Palau Pharma (Spain) | UR-63325 | vestibular disorders | development |
Otorhinolaryngology | Development agreement |
| 2012-07-30 | CytoDyn (Canada) Progenics Pharmaceuticals (USA - NY) | PRO 140 | HIV infection | product acquisition |
Infectious diseases | Product acquisition |
| 2012-07-27 | Roche (Switzerland) Areva (France) | alpha radio-immunotherapy platform | undisclosed malignant disease with a high unmet medical need | R&D |
Cancer - Oncology | R&D agreement |
| 2012-07-26 | Myriad Genetics (USA) PharmaMar (Spain) | BRACAnalysis® (BRCA 1 and BRCA 2 testing) | ovarian cancer, breast cancer | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2012-07-25 | Ark Therapeutics (UK) undisclosed leading European gene therapy company | manufacturing and development services for a therapeutic vaccine product. | undisclosed | manufacturing |
undisclosed | Production agreement |
